Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918094 | 0.87 | NR1H2 (0.42) | NR1H2SLC34A1MAPTESR2MAPK1 | |
| SCHEMBL20392577 | 0.86 | SLC34A1 (0.42) | NR1H2SLC34A1MAPTESR2MAPK1 | |
| SCHEMBL18493673 | 0.86 | SLC34A1 (0.42) | NR1H2SLC34A1MAPTESR2MAPK1 | |
| SCHEMBL6891275 | 0.86 | NR1H2 (0.41) | NR1H2SLC34A1MAPTESR2MAPK1 | |
| SCHEMBL23372979 | 0.85 | NR1H2 (0.40) | NR1H2SLC34A1MAPTESR2MAPK1 | |
| SCHEMBL17561650 | 0.85 | SLC34A1 (0.49) | NR1H2SLC34A1MAPTESR2MAPK1 | |
| SCHEMBL19505292 | 0.85 | PIK3CD (0.35) | MAPTPIK3CDMAPK1NAMPTHPGDS | |
| SCHEMBL20364274 | 0.82 | NR1H2 (0.46) | NR1H2SLC34A1MAPTESR2MAPK1 | |
| SCHEMBL5720871 | 0.82 | NR1H2 (0.42) | NR1H2SLC34A1MAPTESR2MAPK1 | |
| SCHEMBL5720876 | 0.81 | NR1H2 (0.38) | NR1H2SLC34A1MAPTESR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-11912702-B2 | Substituted pyridines as inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912702-B2 | Substituted pyridines as inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3664802-B1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | ALKERMES INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11225475-B2 | Substituted pyridines as inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20210147410-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-05-20 | — | — | US | disclosed |
| WO-2019032528-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | RODIN THERAPEUTICS, INC (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147410-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC3 | NR1H2 150/4885SLC34A1 2659/4885MAPT 1007/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | NR1H2 1135/4885SLC34A1 4204/4885MAPT 3335/4885 |
| US-11225475-B2 | Substituted pyridines as inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC3 | NR1H2 482/4885SLC34A1 1746/4885MAPT 955/4885 |
| US-11912702-B2 | Substituted pyridines as inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC3 | NR1H2 470/4885SLC34A1 1832/4885MAPT 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.